Advertisements

Gyno Trosyd

Quick links to important sections

Gyno Trosyd

Advertisements

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Advertisements

Overview of Gyno Trosyd

Property Description
Active ingredient Tioconazole
Form Vaginal Ovule, Vaginal Cream/Ointment
Pharmacological class Azole Antifungal / Imidazole Derivative
General purpose Elimination of pathogenic yeasts and fungi
Origin Synthetic

Gyno Trosyd is a synthetic pharmaceutical product whose therapeutic core is the single active ingredient, Tioconazole, which belongs to the class of azole antifungal agents. Tioconazole is chemically an imidazole derivative, characterized by a targeting mechanism against fungal pathogens. This compound is clinically recognized for its broad-spectrum activity against pathogenic yeasts and dermatophytes.


Composition and Pharmaceutical Forms

The medication is a single-active-ingredient product, formulated for local application in dosage forms designed to deliver the active component directly to the site of infection. The primary forms include a vaginal ovule and a vaginal cream/ointment. These preparations are intended for the intravaginal or topical route of administration, ensuring the active compound is concentrated locally. A differentiating factor of Tioconazole formulations is its pharmacological suitability for single-dose treatment regimens. This sustained-release capability allows for high therapeutic concentrations while maintaining negligible systemic absorption in non-pregnant patients.


General Therapeutic Purpose and Core Action

The general purpose of Gyno Trosyd is to stop the proliferation and eliminate pathogenic yeasts and fungi through a fungicidal effect. Tioconazole achieves this by interfering with the synthesis of ergosterol, a crucial structural component of the fungal cell membrane. By blocking the creation of this building block, the compound destabilizes the cell wall, ultimately causing the destruction of the fungal cells. This direct fungicidal action against the organism is the foundation of its intended therapeutic purpose, making it a recognized choice for topical mycotic infections.

Advertisements

What side effects are possible with Gyno Trosyd?

Possible side effects and safety information

This section outlines the officially documented adverse effects and safety characteristics of Tioconazole (Gyno Trosyd), as defined in government regulatory labeling.

Adverse Reactions Scope and Classification

The most commonly reported effects are local and generally relate to the application site, classified within System-Organ Classes such as General disorders and administration site conditions and Urogenital system disorders. These reactions often include increased vaginal burning, itching, irritation, redness, or swelling. Mild systemic effects, such as headache or abdominal cramping, have also been reported.

Adverse reactions are formally categorized by frequency in regulatory documents. Uncommon reactions may include dermatitis and rash, while other effects, such as a generalized allergic reaction, bullous eruption, or urticaria, are reported with Frequency Not Known (meaning the incidence cannot be reliably estimated from available data).

Serious Safety Considerations

The most significant safety concern documented is the potential for severe allergic reactions or hypersensitivity. This includes symptoms that could indicate an anaphylactoid reaction, such as difficulty breathing or swelling of the face, lips, tongue, or throat. The medicine is formally contraindicated in individuals with a known history of hypersensitivity to Tioconazole or to any other imidazole antifungal agents.

Constraints and Population Notes

Local irritation is typically transient and mild, often appearing during the first week of treatment. Official safety restrictions advise that the excipients in the vaginal preparations may damage the latex rubber found in condoms or diaphragms, thus potentially reducing the efficacy of these barrier methods. Specific notes regarding pregnancy and lactation indicate that use requires caution, and temporary discontinuation of breast-feeding is recommended by some manufacturers.

Advertisements

Overdose and Emergency Response

Overdose and When to Seek Help

The regulatory information for Gyno Trosyd (Tioconazole) defines overdose through two primary scenarios: accidental oral ingestion and the manifestation of severe allergic reactions.

Overdose resulting from topical or vaginal application is unlikely to occur. Regulatory documents confirm that negligible systemic absorption minimizes the risk of widespread systemic toxicity through the intended local route.

The main documented concern is accidental oral ingestion. If the product is swallowed, an individual must get medical help or contact a Poison Control Center right away, as the medicine may cause harm. The product must be kept out of reach of children due to this specific ingestion risk.

Urgent medical attention is also required immediately if signs of a severe allergic reaction or hypersensitivity develop. These severe outcomes may present as hives, difficult breathing, or swelling of the face, lips, tongue, or throat. Should any of these manifestations occur, the use of the product must be discontinued.

Management for overdose situations, as defined by official labeling, is consistently characterized as symptomatic and supportive therapy, which is instituted following professional assessment.

Advertisements

Therapeutic Uses of Gyno Trosyd

What Gyno Trosyd Treats: Main Uses and Benefits

The therapeutic focus of Gyno Trosyd (Tioconazole) is applied across domains where additional symptomatic support is needed for conditions involving inflammatory or irritative processes. This is primarily used to help manage symptomatic vulvovaginal candidiasis (VVC), commonly known as a vaginal yeast infection.

This medication is also relevant for easing symptoms related to inflammatory or irritative states in certain skin conditions presenting with localized discomfort, including ringworm and jock itch. It is commonly used across conditions presenting with acute or recurrent episodes of candidiasis. The primary symptom clusters it helps manage are symptoms related to physical discomfort, such as vaginal pruritus (itching), burning, and associated soreness.

“The medication is generally considered relevant for maintaining a sense of stability when symptoms are more noticeable.”

Gyno Trosyd offers symptomatic relief that helps patients cope more steadily with symptom fluctuations. It assists with maintaining functional stability, contributing to improved comfort during periods of heightened symptoms.


Quick Fact: Relevant for Symptom Management in Recurrent VVC Episodes

Regulatory References

  1. FDA DailyMed Tioconazole Label
Advertisements

Eligibility and Restrictions for Use

Eligibility Map: Who can and cannot use Gyno Trosyd — Official Regulatory Information

The eligibility profile for Gyno Trosyd (Tioconazole vaginal product) is strictly defined by regulatory documents based on age, prior medical history, and the presence of certain health conditions. This information outlines which populations are established for use and which require medical consultation.

Eligibility Scope Status Defined by Regulator
Populations for whom use is allowed Adults and children 12 years of age and over with a previously diagnosed vaginal yeast infection.
Populations for whom use is contraindicated Individuals with known hypersensitivity to Tioconazole or other imidazole antifungals.
Condition-specific restrictions Use is prohibited for self-treatment if the infection has never been diagnosed by a doctor.
Pregnancy and lactation status Ask a health professional before use (as a general precaution).

Eligibility-related restrictions

Certain factors require a mandatory consultation with a doctor before use, as they may indicate a more serious condition or necessitate a different course of treatment. This includes individuals with diabetes, a weakened immune system (including HIV exposure), or frequently recurring vaginal infections. Additionally, individuals under 12 years of age must seek medical advice, as self-treatment is not established for this group.

Advertisements

What should I know about interactions with other medicines?

Interactions with other medicines and products

Official regulatory information for topical products containing tioconazole primarily addresses interactions involving physically co-administered vaginal and barrier products, rather than pharmacokinetic drug-drug interactions.

Interaction Scope and Restrictions

Co-administration with other vaginal products is subject to specific constraints as outlined in official labeling. Medicinal product categories that have documented interaction-related restrictions include:

  • Vaginal Products: Tampons, douches, spermicides, and other topical vaginal preparations.
  • Latex or Rubber Products: Physical barrier contraceptives, specifically condoms and diaphragms, are subject to mandatory restrictions.

Interaction Basis and Management

The primary mechanistic concern for this product is the potential for the excipients (e.g., mineral oil or petrolatum base) to compromise the physical integrity of latex and rubber materials. This effect is documented to result in a failure of barrier contraceptives to prevent pregnancy or sexually transmitted diseases.

Consequently, the interaction profile establishes specific timing and behavioral rules:

  • During Treatment: The use of tampons, douches, spermicides, or any other vaginal products must be avoided.
  • Contraceptive Use: Reliance on condoms or diaphragms is not advised during treatment. A mandatory waiting period of 3 days following the end of treatment is required before resuming the use of barrier contraceptives made of latex or rubber.

This interaction structure ensures that the safety and efficacy of concurrent physical products are not compromised by the administration of the antifungal medicine.

Advertisements

Mechanism of Action

Targeted Inhibition of Fungal Enzyme Systems

The active ingredient, Tioconazole, exerts its primary action by specifically inhibiting the fungal enzyme lanosterol 14alpha-demethylase (CYP51). This inhibition blocks a critical, early molecular step in the ergosterol biosynthesis pathway, which is essential for the fungal cell's viability. This mechanism initiates a metabolic change resulting in structural compromise.

Disruption of Fungal Cell Membrane Structure

The targeted enzyme inhibition prevents the cell from producing adequate ergosterol while causing the abnormal accumulation of toxic, methylated sterol precursors. This dual effect structurally compromises the fungal cell membrane, leading to a loss of integrity, increased permeability, and the eventual irreversible leakage of vital intracellular components, resulting in a fungicidal effect.

Concentration-Dependent Physiological Outcome

The fungicidal physiological outcome is dependent on achieving and maintaining high local concentrations of Tioconazole at the site of action. This facilitates target engagement and pathway suppression. At lower concentrations, the mechanism's effectiveness is constrained to primarily slow fungal growth (fungistatic effect), which is a key mechanistic limitation.

Advertisements

Dosage and Administration Information

How to Use Gyno Trosyd

Gyno Trosyd (Tioconazole) administration is standardized as a single-dose regimen for local treatment. This usage is defined by its specific route, fixed dosage, and specialized timing.


Official Administration Guidelines

The medication is available in approved forms, such as a 6.5% vaginal ointment or a 300 mg vaginal ovule.

Entity Instruction
Route of Administration Intravaginal route for the ointment or ovule.
Dosing Schedule A single-dose of one full, pre-filled applicator (containing 300 mg of Tioconazole) or one ovule.
Frequency and Timing Administered once only, typically at bedtime (qHS) to support the local action of the drug.
Course Duration The treatment course consists of a one-day administration.

Procedural Structure and Constraints

Age-group administration rules permit use in adults and children 12 years of age and over. The product is ready-to-use and requires no dilution or preparation before the application.

Official step sequence:

  • Timing: The single dose is applied at bedtime.
  • Delivery: The entire contents of the single-use applicator, or the ovule, are inserted into the vagina.
  • Restrictions: The labeling specifies avoiding the use of tampons, douches, spermicides, or other vaginal products during the course of treatment. The product base may interact with latex-based barrier contraceptives.

This structured approach ensures the medication is used precisely for intended local delivery and retention.

Advertisements

Recent Clinical Evidence

Research evidence / Overview of Studies for Gyno Trosyd

Evidence for use in Acute Vaginal Yeast Infections (VVC)

Research into the active ingredient Tioconazole for acute vaginal yeast infections (VVC) has primarily taken the form of Randomized Controlled Trials (RCTs) and systematic reviews. These studies examined the single-dose topical formulation of Tioconazole in research scenarios that included comparison groups receiving other topical or oral antifungal medicines. The studies were conducted on non-pregnant adult women who had been diagnosed with symptomatic VVC confirmed by laboratory tests.

The primary outcomes was observed in this research were Clinical Cure and Mycological Cure. Researchers tracked patient-reported outcomes describing perceived discomfort, such as the resolution of physical discomfort like vaginal itching and burning, as well as tracking the absence of the Candida fungus through laboratory testing. The findings describe patterns observed in these comparative studies, reporting outcomes for Tioconazole that were also tracked for the multi-day comparator treatments. This research provides insight into short-term changes, and these studies contribute to the broader evidence landscape for populations experiencing acute VVC episodes.

Long-term Studies, Follow-up, and Recurrence

Research conducted during periods of increased symptom activity for VVC primarily concentrated on short-term symptom changes within the first one to four weeks following the single application. These follow-up durations were limited and designed to capture the immediate response and symptom patterns. The durability of the effect has not been fully characterized through large, dedicated, long-term RCTs. The research currently available does not determine whether an individual will respond similarly or remain free of symptoms months or a year later. Therefore, there is limited information for long-term outcomes regarding the rates of recurrence of VVC, which is observed in some studies to be a broader limitation for all short-course topical antifungal treatments.

Evidence in Special Populations

The research record for Tioconazole in special populations has not been extensively characterized. Studies have primarily involved healthy, non-pregnant adult women, and results apply only to the populations studied. The available research specifically examining the patterns observed in pregnant women is scarce. Understanding if symptom patterns are different in this population is an area where research remains limited. Similarly, the current research base was not evaluated in children or adolescents, focusing instead on adult women. Consequently, data for certain groups remain insufficient to draw conclusions about its use or the observed patterns in younger populations.

What is Still Uncertain in the Research Record

The research base for Gyno Trosyd highlights what is known, but also where gaps exist in the scientific understanding. The comparative evidence is lacking for large-scale, modern placebo-controlled trials, as most studies research examined Tioconazole in comparison to other active azole medications. The research provides insight into short-term changes, but certainty remains low for long-term outcomes. Overall, research provides context but not individual predictions, and studies contribute to the broader evidence landscape.

Key Studies & References Tioconazole Vaginal Ointment USP, 6.5% - DailyMed Label

Advertisements

Frequently Asked Questions (FAQ)

Common questions about Gyno Trosyd (FAQ)


Q: Can Gyno Trosyd be bought over the counter in some places?

In many jurisdictions, the formulation of Tioconazole 6.5% vaginal ointment is approved for sale as an Over-The-Counter (OTC) product. Official labeling allows for self-treatment of vaginal yeast infections in certain circumstances, such as recurrent infections previously diagnosed by a healthcare professional.


Q: Does Gyno Trosyd treat common fungal infections other than those described in the main use?

Official regulatory documents indicate that Gyno Trosyd vaginal ointment is specifically intended only for the local treatment of vulvovaginal candidiasis (a vaginal yeast infection). The product label does not include other common types of fungal infections.


Q: How quickly does Gyno Trosyd start working after the first use?

Regulatory information indicates that because this is a single-dose treatment, some patients may report experiencing symptom improvement within one day. Follow-up information suggests that full resolution of symptoms may occur over a period of up to seven days.


Q: How long after finishing the treatment should I expect results to be final?

Symptom patterns described in patient information indicate that relief may be fully experienced up to seven days after the single application. Official labeling states that a healthcare professional should be contacted if symptoms do not improve within three days or if they persist after seven days.


Q: Does Gyno Trosyd interact with hormonal birth control pills?

Topical azole antifungals, as a drug class, are generally not associated with reducing the effectiveness of combined hormonal contraceptives. However, the official labeling strongly warns that the product’s excipients may damage latex barrier contraceptives, such as condoms. Any patient with concerns about specific hormonal birth control methods should discuss this with a healthcare professional.


Q: What is the difference between Gyno Trosyd and other similar topical treatments?

Official information indicates that a key feature of Gyno Trosyd is that it is formulated as a single-dose regimen. This differentiates it from many other topical antifungal treatments that require multiple days of use. The active ingredient, Tioconazole, belongs to the broad-spectrum azole antifungal class.


Q: Why do doctors often prescribe Gyno Trosyd instead of other options?

Clinical trial summaries indicate that Gyno Trosyd is approved for a single-dose application. The single-dose regimen is noted in clinical summaries as a feature that offers patient convenience and may support treatment adherence, which are factors considered in prescribing.


Q: What should be done if I experience a severe allergic reaction to Gyno Trosyd?

The medicine is contraindicated (should not be used) if there is a known history of hypersensitivity or severe allergy to Tioconazole. If symptoms that may indicate a severe allergic reaction, such as swelling or difficulty breathing, occur, the appropriate action is to discontinue use and seek immediate emergency medical attention.


Q: Does Gyno Trosyd contain any ingredients that might cause irritation besides the active substance?

The product includes excipients, which are inactive ingredients required for the ointment formula, such as mineral oil or petrolatum base. While local irritation is a common side effect, the labeling primarily warns that the excipients may cause damage to latex or rubber products, such as barrier contraceptives.


Q: Can Gyno Trosyd be used by older women (geriatric population)?

Official regulatory documents state that Gyno Trosyd is approved for use in adults and children 12 years of age and older. No specific difference in safety or effectiveness has been identified for the geriatric population compared to younger adults, based on available product information.


Q: What should be done if some Gyno Trosyd gets into the eye or mouth?

Gyno Trosyd is intended strictly for vaginal use. If the product is accidentally swallowed, official regulatory guidance indicates that a Poison Control Center should be immediately contacted. If the ointment contacts the eyes, the recommended action is to wash them immediately with plenty of water. A doctor should be contacted if irritation persists.


Q: How does Gyno Trosyd's mechanism compare to older antifungal medicines?

Gyno Trosyd (Tioconazole) belongs to the azole antifungal class. It works by interfering with the synthesis of ergosterol, which is a structural component of the fungal cell membrane. This mechanism of action is characteristic of the azole antifungal drug class.


Q: What is the purpose of the applicator that might come with Gyno Trosyd?

Official instructions describe the applicator as a single-use, pre-filled device. Its primary purpose is to ensure that the full dose of the medication is properly measured and delivered into the vagina at the site of the infection.


Q: Why do official guidelines suggest specific application techniques for Gyno Trosyd?

Official product information suggests specific timing, such as administration at bedtime, to achieve the best therapeutic effect. This technique is recommended to promote optimal local delivery and retention of the medicine at the site of infection.


Q: Can I use Gyno Trosyd if I am currently taking other prescribed medication?

The active ingredient in Gyno Trosyd has minimal systemic absorption when applied vaginally in non-pregnant patients, which generally lowers the potential for interacting with oral medications. Official labeling advises that a healthcare professional should be informed of all current medications before treatment begins.


Q: Is Gyno Trosyd safe to use during the menstrual period?

Official labeling advises against using tampons or other vaginal products during the use of Gyno Trosyd. Some product information recommends using unscented sanitary napkins during the menstrual period to manage any leakage and to avoid interfering with the medication’s action.


Q: Can men use Gyno Trosyd to treat certain conditions?

Gyno Trosyd (Tioconazole 6.5% vaginal ointment) is indicated only for the local treatment of vulvovaginal candidiasis in women. It is not approved or labeled by regulatory bodies for use by men.


Q: Is Gyno Trosyd known to interact with alcohol consumption?

Due to its topical route of administration and minimal systemic absorption, no specific interaction between Gyno Trosyd vaginal ointment and alcohol consumption is reported in official labeling.


Q: Do food or drink affect the use of Gyno Trosyd?

Since the product is for topical vaginal use and is not significantly absorbed into the body, official labeling reports no specific warnings regarding food or drink affecting its use.


Q: Are there any warnings about driving or operating machinery while using Gyno Trosyd?

Based on its minimal systemic absorption following vaginal application, Gyno Trosyd is not expected to affect a person’s ability to drive or operate machinery.


Q: What is the common reason for Gyno Trosyd being discontinued early?

Gyno Trosyd is designed as a single-dose treatment, meaning the entire application should be completed at one time. Regulatory guidance indicates that a healthcare professional should be contacted if symptoms worsen or if a severe adverse reaction occurs after administration.


Q: Is Gyno Trosyd only for treatment or can it be used as a preventative measure?

Official regulatory documents indicate that Gyno Trosyd is specifically indicated for the treatment of vulvovaginal candidiasis. It is not approved or labeled for use as a preventative measure against future infections.


Q: Does Gyno Trosyd contain substances regulated under controlled substance acts?

Tioconazole, the active ingredient in Gyno Trosyd, is an antifungal medication. It is not classified as a controlled substance under the U.S. Controlled Substances Act or similar regulations.

Advertisements

How should Gyno Trosyd be stored and disposed of?

Storage and Disposal of Gyno Trosyd (Tioconazole Ointment)

The official labeling provides mandatory requirements for the storage, protection, and disposal of the medicine.

Storage Requirement Condition
Temperature Store at controlled room temperature, 20 C to 25 C (68 F to 77 F).
Prohibited Environment Do not freeze.
Child Safety Keep out of reach of children. If swallowed, contact a Poison Control Center immediately.
Container Integrity Do not use if the sealed foil packet is torn, open, or incompletely sealed.

For disposal, the used applicator and plunger must be removed and placed in the wastebasket; do not flush this component. Any unused or expired medicine should be prepared for disposal in household trash by mixing it with an undesirable substance, such as dirt or used coffee grounds, and placing the mixture in a sealed container.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Gyno Trosyd found in:

A-Z Index: